Amanda Van Swearingen

Publications

Leslie, Patrick L., Yvonne L. Chao, Yi-Hsuan Tsai, Subrata K. Ghosh, Alessandro Porrello, Amanda E. D. Van Swearingen, Emily B. Harrison, et al. “Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.” Nature Communications 10, no. 1 (September 13, 2019): 4192. https://doi.org/10.1038/s41467-019-12222-5.

PMID
31519896
Full Text

Van Swearingen, Amanda E. D., Marni B. Siegel, Allison M. Deal, Maria J. Sambade, Alan Hoyle, D Neil Hayes, Heejoon Jo, et al. “LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.” Breast Cancer Research and Treatment 171, no. 3 (October 2018): 637–48. https://doi.org/10.1007/s10549-018-4852-5.

PMID
29938395
Full Text

Pecot, C., A. Van Swearingen, and B. Papke. “MA27.06 Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA.” In Journal of Thoracic Oncology, 13:S456–S456. Elsevier BV, 2018. https://doi.org/10.1016/j.jtho.2018.08.551.

Full Text

Sambade, Maria, Amanda Van Swearingen, Kaiming Sun, Jing Wang, Kevin Mikule, and Carey K. Anders. “Abstract 2813: Efficacy and pharmacokinetics of niraparib inBRCA-mutant and wild-type intracranial triple negative breast cancer murine models.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2018. https://doi.org/10.1158/1538-7445.am2018-2813.

Full Text

Siegel, Marni B., Xiaping He, Katherine A. Hoadley, Alan Hoyle, Julia B. Pearce, Amy L. Garrett, Sunil Kumar, et al. “Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.” The Journal of Clinical Investigation 128, no. 4 (April 2018): 1371–83. https://doi.org/10.1172/JCI96153.

PMID
29480819
Full Text

Van Swearingen, Amanda E. D., Maria J. Sambade, Marni B. Siegel, Shivani Sud, Robert S. McNeill, Samantha M. Bevill, Xin Chen, et al. “Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.” Neuro Oncology 19, no. 11 (October 2017): 1481–93. https://doi.org/10.1093/neuonc/nox052.

PMID
28486691
Full Text

McNeill, Robert S., Demitra A. Canoutas, Timothy J. Stuhlmiller, Harshil D. Dhruv, David M. Irvin, Ryan E. Bash, Steven P. Angus, et al. “Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.” Neuro Oncology 19, no. 11 (October 2017): 1469–80. https://doi.org/10.1093/neuonc/nox044.

PMID
28379424
Full Text

Swearingen, Amanda ED Van, Maria J. Sambade, Marni B. Siegel, Shivani Sud, Samantha M. Bevill, Brian T. Golitz, Ryan E. Bash, et al. “Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models.” In Model Organisms to Identify Synthetic Lethal Interactions. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-8514.synthleth-a03.

Full Text

Anders, Carey K., Allison Mary Deal, Amanda Elyse Day Van Swearingen, Marni Siegel, David N. Hayes, Heejoon Jo, Paul Little, et al. “LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).” In Journal of Clinical Oncology, 35:1011–1011. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.1011.

Full Text

Pages